Market ExpansionVRDN-003’s TPP as a low-volume, self-administered autoinjector will be preferred by the majority of patients and could help expand the overall TED market.
PartnershipsVRDN announced an exclusive license agreement with Kissei Pharmaceutical to develop and commercialize Veli and VRDN-003 in Japan, providing important clinical and regulatory validation.
Regulatory ApprovalsThe FDA granted veligrotug Breakthrough Therapy Designation based on its rapid onset of proptosis response and robust improvement/resolution of diplopia in chronic TED patients.